{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:22:30Z","timestamp":1792891350618,"version":"4.5.0"},"reference-count":38,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments\u00a0and healthcare resource utilization (HCRU) associated with MG exacerbation.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            This was a retrospective analysis of adult patients with MG identified by commercial, Medicare\u00a0or Medicaid insurance claims from the IBM\n            <jats:sup>\u00ae<\/jats:sup>\n            MarketScan\n            <jats:sup>\u00ae<\/jats:sup>\n            database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12\u00a0months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12\u00a0weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period.\n            <jats:bold>Results:<\/jats:bold>\n            Among 9352 prevalent MG patients, 34.4% (n\u00a0=\u00a03218) experienced \u22651 exacerbation after index: commercial, 53.0% (n\u00a0=\u00a01706); Medicare, 39.4% (n\u00a0=\u00a01269); and Medicaid, 7.6% (n\u00a0=\u00a0243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with \u22651 exacerbation. Mean total MG-related healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0108","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T11:33:31Z","timestamp":1702640011000},"source":"Crossref","is-referenced-by-count":14,"title":["Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data"],"prefix":"10.57264","volume":"13","author":[{"given":"Julia","family":"Pisc","sequence":"first","affiliation":[{"name":"Aetion Inc., New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ting","sequence":"additional","affiliation":[{"name":"UCB Pharma, Atlanta, GA\u00a030080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Skornicki","sequence":"additional","affiliation":[{"name":"Aetion Inc., New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sinno","sequence":"additional","affiliation":[{"name":"UCB Pharma, Atlanta, GA\u00a030080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[{"name":"UCB Pharma, Atlanta, GA\u00a030080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat. Rev. Dis. Primers 5(1), 30 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel VC","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J. Rare Dis. 2, 44 (2007).","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society","volume":"263","author":"Melzer N","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J. Neurol. 263(8), 1473\u20131494 (2016).","journal-title":"J. Neurol."},{"key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"886625","DOI":"10.3389\/fneur.2022.886625","article-title":"Corticosteroid treatment-resistance in myasthenia gravis","volume":"13","author":"Kaminski HJ","year":"2022","unstructured":"Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front. Neurol. 13, 886625 (2022).","journal-title":"Front. Neurol."},{"key":"e_1_3_10_7_2","unstructured":"Myasthenia Gravis Foundation of America. Clinical overview of MG. https:\/\/myasthenia.org\/Professionals\/Clinical-Overview-of-MG (2023)."},{"issue":"3","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3), 114\u2013122 (2021).","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4), 419\u2013425 (2016).","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis C","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol. Clin. 36(2), 311\u2013337 (2018).","journal-title":"Neurol. Clin."},{"key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon D","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front. Neurol. 11, 538 (2020).","journal-title":"Front. Neurol."},{"issue":"7","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas MC","year":"2022","unstructured":"Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev. Clin. Immunol. 18(7), 691\u2013701 (2022).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza R","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther. Adv. Neurol. Disord. 11, 1756285617749134 (2018).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"e_1_3_10_14_2","unstructured":"Myasthenia Gravis Foundation of America. MG emergencies. https:\/\/myasthenia.org\/MG-Community\/-MG-Emergencies#:\u223c:text=MG%20Exacerbations%20%26%20Crisis&text=An%20exacerbation%2C%20or%20flare%2C%20is and%2F%20or%20become%20more%20severe (2023)."},{"issue":"3","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb JP","year":"2014","unstructured":"Sieb JP. Myasthenia gravis: an update for the clinician. Clin. Exp. Immunol. 175(3), 408\u2013418 (2014).","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard JF","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16(12), 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"175628642211503","DOI":"10.1177\/17562864221150327","article-title":"Healthcare resource use in myasthenia gravis: a US health claims analysis","volume":"16","author":"Mahic M","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther. Adv. Neurol. Disord. 16, 17562864221150327 (2023).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"120531","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting A","year":"2023","unstructured":"Ting A, Story T, Lecomte C, Estrin A, Syed S, Lee E. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. J. Neurol. Sci. 445, 120531 (2023).","journal-title":"J. Neurol. Sci."},{"key":"e_1_3_10_19_2","unstructured":"Klaisner JK Schweitzer K Ally AJ. Myasthenia gravis patient payer channel distribution. https:\/\/uk.milliman.com\/en-GB\/insight\/myasthenia-gravis-patient-payer-channel-distribution (2022)."},{"issue":"2","key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1162\/qjec.2009.124.2.597","article-title":"Does Medicare save lives?","volume":"124","author":"Card D","year":"2009","unstructured":"Card D, Dobkin C, Maestas N. Does Medicare save lives? Q. J. Econ. 124(2), 597\u2013636 (2009).","journal-title":"Q. J. Econ."},{"key":"e_1_3_10_21_2","unstructured":"Center on Budget Policy Priorities. Policy basics: Introduction to Medicaid. https:\/\/www.cbpp.org\/research\/health\/introduction-to-medicaid (2020)."},{"issue":"1","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc AM","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J. Med. Life 14(1), 7\u201316 (2021).","journal-title":"J. Med. Life"},{"key":"e_1_3_10_23_2","unstructured":"US Bureau of Labor Statistics. CPI for all Urban Consumers (CPI-U). https:\/\/www.bls.gov (2021)."},{"issue":"1","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra UK","year":"2020","unstructured":"Misra UK, Kalita J, Singh VK, Kumar S. A study of comorbidities in myasthenia gravis. Acta Neurol. Belg. 120(1), 59\u201364 (2020).","journal-title":"Acta Neurol. Belg."},{"issue":"4","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan J","year":"2021","unstructured":"Vijayan J, Menon D, Barnett C, Katzberg H, Lovblom LE, Bril V. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve 64(4), 462\u2013466 (2021).","journal-title":"Muscle Nerve"},{"issue":"5","key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mus.27331","article-title":"Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study","volume":"64","author":"Thomsen JLS","year":"2021","unstructured":"Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve 64(5), 538\u2013544 (2021).","journal-title":"Muscle Nerve"},{"issue":"4","key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.27659","article-title":"One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG Patient Registry","volume":"66","author":"Lee I","year":"2022","unstructured":"Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG Patient Registry. Muscle Nerve 66(4), 411\u2013420 (2022).","journal-title":"Muscle Nerve"},{"issue":"1","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","article-title":"Gender differences in quality of life among patients with myasthenia gravis in China","volume":"18","author":"Dong D","year":"2020","unstructured":"Dong D, Chong MK-C, Wu Y, Kaminski H, Cutter G, Xu X Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual. Life Outcomes 18(1), 296 (2020).","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000512077","article-title":"Exacerbation rate in generalized myasthenia gravis and its predictors","volume":"84","author":"Abuzinadah AR","year":"2021","unstructured":"Abuzinadah AR, Alanazy MH, Butt NS, Barohn RJ, Dimachkie MM. Exacerbation rate in generalized myasthenia gravis and its predictors. Eur. Neurol. 84(1), 43\u201348 (2021).","journal-title":"Eur. Neurol."},{"issue":"4","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/genes13040696","article-title":"Preferential X chromosome inactivation as a mechanism to explain female preponderance in myasthenia gravis","volume":"13","author":"Nicoli V","year":"2022","unstructured":"Nicoli V, Tabano SM, Colapietro P, Maestri M, Ricciardi R, Stoccoro A Preferential X chromosome inactivation as a mechanism to explain female preponderance in myasthenia gravis. Genes 13(4), 696 (2022).","journal-title":"Genes"},{"issue":"20","key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","article-title":"Increased risk for clinical onset of myasthenia gravis during the postpartum period","volume":"87","author":"Boldingh MI","year":"2016","unstructured":"Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekj\u00e6r H, Verschuuren JJ, Tallaksen CM. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology 87(20), 2139\u20132145 (2016).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-510X(98)00031-8","article-title":"Exacerbation of myasthenia gravis during the menstrual period","volume":"156","author":"Leker RR","year":"1998","unstructured":"Leker RR, Karni A, Abramsky O. Exacerbation of myasthenia gravis during the menstrual period. J. Neurol. Sci. 156(1), 107\u2013111 (1998).","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"e_1_3_10_33_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20(7), 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"e_1_3_10_34_2","first-page":"EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu T","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evidence 1, EVIDoa2100066 (2022).","journal-title":"NEJM Evidence"},{"issue":"5","key":"e_1_3_10_35_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril V","year":"2023","unstructured":"Bril V, Druzdz A, Grosskreutz J Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 22(5), 383\u2013394 (2023).","journal-title":"Lancet Neurol."},{"issue":"5","key":"e_1_3_10_36_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard JF","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 22(5), 395\u2013406 (2023).","journal-title":"Lancet Neurol."},{"issue":"3","key":"e_1_3_10_37_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population","volume":"45","author":"Guptill JT","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve 45(3), 363\u2013366 (2012).","journal-title":"Muscle Nerve"},{"issue":"6","key":"e_1_3_10_38_2","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/mus.25624","article-title":"Inpatient cost analysis for treatment of myasthenia gravis","volume":"56","author":"Omorodion JO","year":"2017","unstructured":"Omorodion JO, Pines JM, Kaminski HJ. Inpatient cost analysis for treatment of myasthenia gravis. Muscle Nerve 56(6), 1114\u20131118 (2017).","journal-title":"Muscle Nerve"},{"issue":"7","key":"e_1_3_10_39_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt E","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmuller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics 38(7), 715\u2013728 (2020).","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"e_1_3_10_40_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000524733","article-title":"Are there racial differences in inpatient outcomes and treatment utilization following hospitalization for myasthenia gravis exacerbation?","volume":"56","author":"Syed MJ","year":"2022","unstructured":"Syed MJ, Khawaja A, Lisak RP. Are there racial differences in inpatient outcomes and treatment utilization following hospitalization for myasthenia gravis exacerbation? Neuroepidemiology 56(5), 380\u2013388 (2022).","journal-title":"Neuroepidemiology"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T11:37:19Z","timestamp":1704454639000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.57264\/cer-2023-0108"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0108","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"e230108"}}